Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 2, 1996, Pages 183-186

  Keidar, Shlomo ^a   Oiknine, Judith ^a   Leiba, Adi ^b   Shapira, Chen ^b   Leiba, Marcel ^b   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

Angiotensin converting enzyme inhibitors; Fosinopril; Hypertension; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOSINOPRIL; FOSINOPRILAT;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PLATELETS; FOSINOPRIL; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRODRUGS;

EID: 0030032382     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199602000-00002     Document Type: Article

References (27)

1. Aviram M. Effect of lipoproteins and platelets on macro-phage cholesterol metabolism. Blood Cell Biochem 1992;2: 179-207.
2. Aviram M. Platelets and the arterial wall lesion. Curr Opin Lipidol 1992;3:344-8.
3. Ross R. Pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314:488-500.
4. Aviram M, Rosenblat M, Brook JG. Secretory products from human monocyte-derived macrophages enhance platelet aggregation. Metabolism 1991;40:270-4.
5. Fuhrman B, Brook JG, Aviram M. Activated platelets secrete a protein-like factor that stimulates oxidized-LDL receptor activity in macrophages. J Lipid Res 1991;32:1113-23.
6. Kowala M, Grove RI, Abery G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters: fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
7. Jacobsson LS, Person K, Aberg G, Andersson RGG, Karlberg BE, Olsson AG. Antiatherosclerotic effects of the an- giotensin converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994;24:670-7.
8. Vlachakis ND, Alebort L. Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980;45:321-5.
9. Zannad F, Bray-Desboscs L, Ghawi R, Donner M, Thibout E, Stoltz JF. Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. J Hypertens 1993;11:559-64.
10. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991;17:13-9.
11. Someya N, Norotomir Y, Kodama K, et al. Suppressive effects of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984;6:840-3.
12. Anderson NJ, Duchin KL, Gore RD, et al. Once daily fosinopril in the treatment of hypertension. Hypertension 1991; 17:636-42.
13. Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther 1990;12:520-33.
14. Murdoch D, McTavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992;43: 123-40.
15. Weber MA. Fosinopril: a new generation of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20(suppl S:7-12.
16. Guthrie R. Fosinopril: an overview. Am J Cardiol 1993;72: 22H-4H.
17. Born GVR. Aggregation of blood platelets by adenosine biphoshpate and its reversal. Nature 1962;194:297-300.
18. Mustard JF, Kinlough-Rathbone RL, Packham MA. Platelet activation an overview. PAF Platelets Asthma 1987;21:23-36.
19. James IN, Dickenson EJ, Burgoyne W, et al. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988;2:21-5.
20. Islim IF, Beevers DG, Bareford D. The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension. J Hypertens 1992;10:379-83.
21. Gill J, Fonseca V, Dandona P, Jeremy JY. Lisinopril and nifedipine administration inhibits the ex vivo uptake of (45Ca2+) by platelets from hypertensive diabetic patients. Br J Clin Pharmacol 1992;33:161-5.
22. Keilani T, Schlueter WA, Levin ML, Battle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993;118:246-54.
23. Allemann Y, Baumann S, Jost M, et al. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. Eur J Clin Pharmacol 1992; 42:275-80.
24. De Lecuw PW, De Bos R, Van Es PN, Birhenhagen WH. Blood platelets and angiotensin II. J Hypertens 1984;2 (suppl):5225-6.
25. Moore TJ, Williams GH. Angiotensin II receptors on human platelets. Circ Res 1982;51:314-20.
26. Moore TJ, Taylor T, William GH. Human platelet angiotensin II receptors: regulation by the circulating angiotensin level. J Clin Endocrinol Metab 1984;58:778-82.
27. Swartz SL, Moore TJ. Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. Thromb Haemost 1990;63:87-90.